# Yale Cancer Center NCTN LAPS

> **NIH NIH UG1** · YALE UNIVERSITY · 2022 · $484,894

## Abstract

Project Summary
Yale Cancer Center's continuing participation in the NCTN under the leadership of Dr. Charles
Fuchs includes not only a solid history of strong and committed accrual to NCTN trials, but
strong leadership in the trials efforts at SWOG and other groups. YCC remains committed to
prioritizing NCTN trials at all the YCC clinical centers and demonstrates annual accrual beyond
estimates developed in our current U10 award. For this current submission, the vision of the
YCC leadership is to: 1) continue to prioritize NCTN trials for accrual and develop YCC as a
major contributor to group trials with additional contribution of our Care Centers; 2) facilitate and
encourage YCC faculty to assume leadership roles in SWOG and other NCTN groups by
supporting their time and effort and rewarding these activities; and 3) leverage our NCTN
Coordinating Committee (NCC) as a bridge to bring Yale translational science to group
activities as the results of our investigator initiated pilot trials become promising for multi-center
and randomized questions. In addition to the leadership efforts of Dr. Fuchs, other key SWOG
leaders include Drs. Roy Herbst, Daniel Petrylak and Lajos Pusztai. Drs. Peter Glazer, Roy
Decker and Alessandro Santin will lead our efforts in the NRG group in addition to Dr. Barbara
Burtness who will continue to lead our efforts in the ECOG-ACRIN group. We believe that the
science and translational work at YCC has strong potential for incorporation into NCTN
programs. Continued work on early phase drug development, EGFR resistance, PD-1 signaling,
chemical biology, and new targets in signal transduction through the scientific programs of YCC
have strong potential for translation into group trials. Furthermore, with expansion of the Smilow
Cancer Hospital Care Centers, we demonstrated a greater opportunity to bring NCTN trials to
the greater patient population across the state of Connecticut. This UG1 grant will assist us in
developing the appropriate leadership and infrastructure for support of key NCTN group efforts
in both accrual and program development.

## Key facts

- **NIH application ID:** 10359158
- **Project number:** 5UG1CA233337-04
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Roy S Herbst
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $484,894
- **Award type:** 5
- **Project period:** 2019-03-08 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10359158

## Citation

> US National Institutes of Health, RePORTER application 10359158, Yale Cancer Center NCTN LAPS (5UG1CA233337-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10359158. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*